Memantine Augmentation of Lamotrigine Incomplete-Response in Bipolar Depression
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate whether addition of memantine to bipolar
depression patients who have had an incomplete response to lamotrigine (Lamictal) which is
frequently used to treat bipolar depression in the clinical setting. At present, memantine is
approved for use in the treatment of Alzheimer's disease or dementia, but not for use for the
treatment of bipolar depression. Subjects will be asked to participate because they are
suffering from bipolar depression associated and have had an inadequate response to
lamotrigine. Subjects will have to be on at least 100 mg per day, for at least 4 weeks.